A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer

Drug Development Research

Volumn 76, Issue 6, 2015, Pages 263-269

  Zhou, Joseph Yi ^a   Xu, Biao ^b   Li, Lixin ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c CENTRAL MICHIGAN UNIVERSITY   (United States)

Author keywords

anticancer drug; biomarker; metformin; microRNA; type 2 diabetes

Indexed keywords

HMGA1 PROTEIN; LET 7A; METFORMIN; MICRORNA; MICRORNA 145; MICRORNA 193B; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 26; PROTEIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; CARCINOGENESIS; COLON CANCER; DIABETES MELLITUS; DIABETIC PATIENT; GENE CONTROL; GENE FUNCTION; GENE TARGETING; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ONCOGENE; PANCREAS CANCER; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; ANIMAL; DIABETES MELLITUS, TYPE 2; GENETICS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MICRORNAS; NEOPLASMS;

EID: 84941210648     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21265     Document Type: Review

References (52)

1. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH., 2010. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70: 3606-3617.
2. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD., 2009. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-915.
3. Avci CB, Harman E, Dodurga Y, Susluer SY, Gunduz C., 2013. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev 14: 765-768.
4. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, et al., 2012a. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72: 335-345.
5. Bao B, Azmi AS, Ali S, Zaiem F, Sarkar FH., 2014. Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med 2: 59.
6. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, et al., 2012b. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 5: 355-364.
7. Bartel DP., 2009. MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
8. Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S, et al., 2012. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun 3: 865.
9. Bowker SL, Majumdar SR, Veugelers P, Johnson JA., 2006. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care 29: 1990-1991.
10. Bushati N, Cohen SM., 2007. MicroRNA functions. Annu Rev Cell Dev Biol 23: 175-205.
11. Bye A, Røsjø H, Aspenes ST, Condorelli G, Omland T, Wisløff U., 2013. Circulating microRNAs and aerobic fitness-the HUNT-Study. PLoS One 8: e57496.
12. Carthew RW, Sontheimer EJ., 2009. Origins and Mechanisms of miRNAs and siRNAs. Cell 136: 642-655.
13. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK., 2010. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer 1: 306-319.
14. Coleman CB, Lightell DJ, Moss SC, Bates M, Parrino PE, Woods TC., 2013. Elevation of miR-221 and -222 in the internal mammary arteries of diabetic subjects and normalization with metformin. Mol Cell Endocrinol 374: 125-129.
15. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A., 2009. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem 284: 3728-3738.
16. De Vito C, Riggi N, Suvà ML, Janiszewska M, Horlbeck J, Baumer K, Provero P, Stamenkovic I., 2011. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. PLoS One 6: e23592.
17. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD., 2005. Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.
18. Gallagher EJ, LeRoith D., 2011. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 1243: 54-68.
19. Gauthier BR, Wollheim CB., 2006. MicroRNAs: 'ribo-regulators' of glucose homeostasis. Nat Med 12: 36-38.
20. Hua S, Xiaotao X, Renhua G, Yongmei Y, Lianke L, Wen G, Yongqian S., 2012. Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. Biomed Pharmacother 66: 89-97.
21. Huang Y., 2012. A mirror of two faces: lin28 as a master regulator of both miRNA and mRNA. Wiley Interdiscip Rev RNA 3: 483-494.
22. Iorio MV, Croce CM., 2012. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4: 143-159.
23. Ishihara K, Sasaki D, Tsuruda K, Inokuchi N, Nagai K, Hasegawa H, Yanagihara K, Kamihira S., 2012. Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol 36: 560-565.
24. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, et al., 2009. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480.
25. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al., 2012. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 11: 549-60.
26. Kurisetty VV, Lakshmanaswamy R, Damodaran C., 2014. Pathogenic and therapeutic role of miRNAs in breast cancer. Front Biosci (Landmark Ed) 19: 1-11.
27. Ladomery MR, Maddocks DG, Wilson ID., 2011. MicroRNAs: their discovery, biogenesis, function and potential use as biomarkers in non-invasive prenatal diagnostics. Int J Mol Epidemiol Genet 2: 253-260.
28. Li W, Yuan Y, Huang L, Qiao M, Zhang Y., 2012. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 96: 187-195.
29. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM., 2009. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-5.
30. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD., 2009a. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031-2040.
31. Liu X, Cheng Y, Yang J, Xu L, Zhang C., 2012. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol 52: 245-255.
32. Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C., 2009b. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 104: 476-87.
33. Ma G, Wang Y, Li Y, Cui L, Zhao Y, Zhao B, Li K., 2015. MiR-206, a key modulator of skeletal muscle development and disease. Int J Biol Sci 11: 345-352.
34. McCarty MF., 2012. Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression. Med Hypotheses 78: 262-269.
35. Nangia-Makker P, Yu Y, Vasudevan A, Farhana L, Rajendra SG, Levi E, Majumdar AP., 2014. Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One 9: e84369.
36. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, Menendez JA., 2011. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 10: 1144-1151.
37. Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N, Sabater M, Gõmez-Ambrosi J, Anglada R, Fernández-Formoso JA, Ricart W, et al., 2013. Targeting the circulating microRNA signature of obesity. Clin Chem 59: 781-792.
38. Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E, Xifra G, Martínez C, Ricart W, Rieusset J, et al., 2014. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care 37: 1375-1383.
39. Pang Y, Young CY, Yuan H., 2010. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 42: 363-369.
40. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P, et al., 2004. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432: 226-230.
41. Pulito C, Donzelli S, Muti P, Puzzo L, Strano S, Blandino G., 2014. MicroRNAs and cancer metabolism reprogramming: the paradigm of metformin. Ann Transl Med 2: 58.
42. Rachagani S, Kumar S, Batra SK., 2010. MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett 292: 8-16.
43. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, et al., 2012. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 7: e29770.
44. Serpico D, Molino L, Di Cosimo S., 2014. MicroRNAs in breast cancer development and treatment. Cancer Treat Rev 40: 595-604.
45. Shiotani A, Murao T, Kimura Y, Matsumoto H, Kamada T, Kusunoki H, Inoue K, Uedo N, Iishi H, Haruma K., 2013. Identification of serum miRNAs as novel non-invasive biomarkers for detection of high risk for early gastric cancer. Br J Cancer 109: 2323-2330.
46. Sun LL, Jiang BG, Li WT, Zou JJ, Shi YQ, Liu ZM., 2011. MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res Clin Pract 91: 94-100.
47. van der Kolk JH, Pacholewska A, Gerber V., 2015. The role of microRNAs in equine medicine: a review. Vet Q 35: 1-16.
48. Vatandoost N, Ghanbari J, Mojaver M, Avan A, Ghayour-Mobarhan M, Nedaeinia R, Salehi R., 2015. Early detection of colorectal cancer: from conventional methods to novel biomarkers. J Cancer Res Clin Oncol. 2015 February. DOI: 10.1007/s00432-015-1928-z.
49. Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK., 2014. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer 5: 374-389.
50. Wang Y, Dai W, Chu X, Yang B, Zhao M, Sun Y., 2013. Metformin inhibits lung cancer cells proliferation through repressing microRNA-222. Biotechnol Lett 35: 2013-2019.
51. Yu Y, Kanwar SS, Patel BB, Oh PS, Nautiyal J, Sarkar FH, Majumdar AP., 2012. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells. Carcinogenesis 33: 68-76.
52. Zhou JY, Li L., 2014. MicroRNAs are key regulators of brown adipogenesis. Biochim Biophys Acta 1841: 1590-1595.